ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer (EROS)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
80 participants
Aug 5, 2024
OBSERVATIONAL
Conditions
Summary
Although many phase III clinical trials evaluate the quality of life as a secondary endpoint, male sexuality remains a neglected topic in oncology research. In light of the long-term efficacy of new-generation anticancer treatments for ANSCLC (i.e. targeted therapies and immunotherapy), there is a paucity of data about any detrimental effect on fertility and sexuality that could complicate the therapy proposal, especially in young patients. The aim of this trial is to assess incidence of endocrine toxicity and sexual dysfuction in male patients receiving active treatment for ANSCLC
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Alectinib 600 mg/BID
180 mg/daily
100 mg/daily
80 mg/daily
960 mg/daily
150 mg/BID
2 mg/daily
160 mg/BID
200 mg intravenous every 21 days
350 mg intravenous every 21 days
240 mg intravenous every 14 days
AUC4/AU5 intravenous every 21 days
500 mg/mq intravenous every 21 days
175 mg/mq intravenous every 21 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06532149